Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

NCT03206060 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

130

Enrollment

NIH

Sponsor class

Conditions

Pheochromocytoma
Paraganglioma
Neuroendocrine Tumors
Neuroendocrine Neoplasms

Interventions

DRUG: Lu-177-DOTATATE
DRUG: Ga-68-DOTATATE

Sponsor

National Cancer Institute (NCI)